Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

Clark Golestani Biography and Net Worth

EVP of Merck & Co., Inc.

Clark Golestani has over 30 years of experience in health, life sciences and technology, and is an active investor, advisor and board member with a focus on the healthcare, life science and technology, media, and telecommunications (TMT) sectors. Mr. Golestani currently serves as the managing director of C Sensei Group, LLC an advisory services firm, as a senior advisor to New Mountain Capital based in New York City, NY, as an investment advisor to The CXO Fund based in Palo Alto, CA, a special advisor to the Dean at the University of Texas at Austin, Dell Medical School, and as a member of the DIA – Science and Policy Advisory Council.

What is Clark Golestani's net worth?: The estimated net worth of Clark Golestani is at least $1.67 million as of May 20th, 2016. Mr. Golestani owns 17,083 shares of Merck & Co., Inc. stock worth more than $1,674,988 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Golestani may own. Learn More about Clark Golestani's net worth.
How do I contact Clark Golestani?: The corporate mailing address for Mr. Golestani and other Merck & Co., Inc. executives is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. Merck & Co., Inc. can also be reached via phone at (908) 740-4000 and via email at [email protected]. Learn More on Clark Golestani's contact information.
Has Clark Golestani been buying or selling shares of Merck & Co., Inc.?: Clark Golestani has not been actively trading shares of Merck & Co., Inc. during the last quarter. Most recently, Clark Golestani sold 3,000 shares of the business's stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $63.03, for a transaction totalling $189,090.00. Learn More on Clark Golestani's trading history.
Who are Merck & Co., Inc.'s active insiders?: Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Ashley Watson (SVP), and Wendell Weeks (Director). Learn More on Merck & Co., Inc.'s active insiders.
Are insiders buying or selling shares of Merck & Co., Inc.?: During the last year, insiders at the sold shares 2 times. They sold a total of 51,694 shares worth more than $6,545,285.10. The most recent insider tranaction occured on February, 13th when insider Joseph Romanelli sold 1,000 shares worth more than $124,890.00. Insiders at Merck & Co., Inc. own 0.1% of the company. Learn More about insider trades at Merck & Co., Inc..
Information on this page was last updated on 2/13/2024.

Clark Golestani Insider Trading History at Merck & Co., Inc.

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/10/2016	Sell	3,000	$63.03	$189,090.00
5/20/2016	Sell	39,877	$54.79	$2,184,860.83	17,083
2/14/2014	Sell	5,990	$55.47	$332,265.30	6,046

Clark Golestani Buying and Selling Activity at Merck & Co., Inc.

Merck & Co., Inc. Company Overview

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Today's Range

Now: $98.05

$97.90

$99.68

50 Day Range

MA: $102.25

$96.30

$111.54

2 Week Range

Now: $98.05

$94.48

$134.63

Volume

29,272,893 shs

Average Volume

9,418,368 shs

Market Capitalization

$248.03 billion

P/E Ratio

20.56

Dividend Yield

3.02%

Beta

0.39

AI breakthrough about to upend industry

From Porter & Company | Ad

I urge you to watch it now.